Medical Device Pen Testing: Choosing the Right Provider

Part of our Medical device penetration testing series. For the full overview, start with FDA Penetration Testing Requirements for Medical Devices.

When penetration test reports are vague, incomplete, or written to enterprise IT standards rather than medical device requirements, FDA reviewers issue deficiencies that can delay clearance, sometimes requiring a full re-test before you can respond. If you’re selecting a provider for medical device pen testing, the wrong choice doesn’t just waste budget. It can push your submission timeline back by months at the worst possible point in your development cycle.

Many general IT security firms lack the medical device-specific experience needed to produce FDA submission evidence or frame findings around patient safety risk. They know how to run a test, but producing documentation that survives FDA review is a different skill set. That gap is exactly why firms like Blue Goat Cyber exist: to bridge technically competent testing with submission-ready evidence that regulators can actually evaluate.

This guide covers everything you need to make a qualified decision: scope and methodology, regulatory standards, provider qualifications, realistic costs and timelines, and the specific questions to ask before you sign a contract.

Key Takeaways

• FDA submission reports differ substantially from corporate IT reports.
• Patient safety impacts must drive risk assessment, not just CVSS scores.
• Provider must have medical device, not just healthcare IT, experience.
• Align testing scope with your device's threat model and SBOM.
• Validate provider's track record for FDA-accepted reports.
• Ensure the report maps to FDA premarket guidance and ISO 14971.

Table of Contents

• Key Takeaways
• What medical device penetration testing actually covers
• How medical device pen testing differs from standard IT security testing
• Regulatory standards your pen test must satisfy
• Firmware and hardware pen testing: IVDs and other device categories
• What qualifications to require from a testing provider
• What pen testing costs and how long it takes
• Questions to ask before you sign a contract
• Choosing right the first time

Why this matters

The FDA's Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to medical device pen testing the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023.

Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap.

What medical device penetration testing actually covers

A qualified medical device security test is not a network scan with a PDF report attached. It covers every layer of your device’s attack surface, from physical hardware to the cloud backend, and the scope must be documented before a single test begins. For an overview of the common testing approaches by system component, see our guide to types of penetration testing for medical device cybersecurity.

Hardware and firmware: the physical attack surface

Physical ports, debug interfaces like JTAG and UART, bootloaders, and chips are all in scope for a thorough hardware assessment. Testers evaluate tamper resistance, side-channel vulnerabilities, and whether physical access to the device yields meaningful leverage for an attacker. This kind of firmware and hardware pen testing requires specialized lab equipment and embedded systems expertise that many standard IT penetration testers lack.

Firmware analysis goes deeper: static binary analysis, boot-chain integrity validation, and a review of the embedded OS for known CVEs and misconfigurations. Testers also examine secure boot mechanisms, cryptographic implementations, and firmware update security. If your firmware can be modified without authentication, that’s a patient safety issue, not just a compliance checkbox.

Wireless protocols, companion apps, and cloud backend

Wireless scope includes Wi-Fi, Bluetooth, ZigBee, RFID, and any proprietary radio protocols your device uses to communicate. Testers look for protocol weaknesses, denial-of-service vectors via electromagnetic manipulation, and whether communications are properly encrypted end-to-end. Research consistently shows wireless vulnerabilities are among the most exploitable in connected medical devices, which makes this portion of the engagement non-negotiable.

Companion app testing focuses on authentication flaws, data exposure, and how the app integrates with the device itself. The cloud backend assessment covers API security, access controls, infrastructure configuration, and data storage practices. A weakness in your cloud API can be just as dangerous as a firmware flaw, especially when the backend controls device behavior or stores patient data.

Why scope definition determines FDA submission quality

An incomplete scope produces an incomplete report, and the FDA will notice. If your submission lists communication interfaces that your penetration test report doesn’t address, you’ll receive a deficiency asking you to explain the gap, which means either a re-test or a detailed justification for why certain components were excluded.

Your scope document must map directly to your device’s threat model and match the interfaces described in your submission. Your SBOM should also inform scope by surfacing third-party components that need their own assessment. If your device runs a Linux-based embedded OS with open-source networking libraries, those components need to be explicitly addressed in the testing scope. For a practical, step-by-step approach to building a defensible scope document, refer to our article on scoping a medical device penetration test.

How medical device pen testing differs from standard IT security testing

Enterprise IT security and medical device security share tools and techniques, but they operate under fundamentally different consequence models, and that difference shapes everything from how findings are framed to what the final report must contain.

Patient safety changes the entire risk equation

In enterprise IT, a compromised system means data loss or downtime. In a medical device, it can mean a patient receives the wrong therapy, receives no therapy at all, or receives incorrect diagnostic information that drives a harmful clinical decision. That changes how every finding must be framed and evaluated.

Findings must be assessed in terms of patient harm potential, not just CVSS scores. FDA risk analysis follows ISO 14971, not standard vulnerability severity matrices. A medium-CVSS finding that could allow unauthorized modification of insulin delivery parameters is far more significant than a critical-CVSS finding with no pathway to patient harm. Testers must understand this distinction and write their reports accordingly, and they must apply non-disruptive testing protocols in clinical or patient-connected contexts, where triggering a device fault during a test is not acceptable.

Regulatory evidence requirements vs. corporate compliance reports

Enterprise pen test reports summarize findings and recommend patches. FDA pen test reports must document tester independence, testing scope, methodology, all exploitation attempts whether successful or not, patient harm impact assessment, and mitigation rationale for any unresolved finding. The evidentiary bar is categorically different.

A corporate IT pen test report rarely satisfies what the FDA expects in a premarket submission. Medical device penetration testing is a distinct discipline, not simply IT testing applied to a new type of hardware. The technical execution may look similar on the surface. The documentation requirements are an entirely different undertaking.

Regulatory standards your pen test must satisfy

Which standards govern your submission determines what goes into the report and what FDA reviewers will check when they evaluate your cybersecurity documentation. Know this before you evaluate a single provider.

FDA premarket guidance and what reviewers expect to see

FDA’s premarket cybersecurity guidance, most recently updated in 2023 and further refined in 2026, explicitly recommends penetration testing as part of cybersecurity verification and validation. Requirements took effect for submissions on or after March 29, 2023, and apply to 510(k), PMA, De Novo, and related pathways for devices with cybersecurity risk. For a detailed discussion of how to structure pen test deliverables to align with reviewer expectations, see Penetration Testing for Medical Devices: What The FDA Expects.

Per FDA guidance, reviewers expect a report that covers: a device description and communication methods, testing timeframe and methodology, tester credentials and independence, a full account of vulnerabilities exploited, technical effects on safety and effectiveness, and a patient harm matrix. CVSS scores alone are not sufficient. Risk must be mapped to safety impacts across confidentiality, integrity, and availability dimensions. If your provider can’t produce that structure, their report will generate deficiencies.

UL 2900, ISO 14971, and supporting frameworks

UL 2900-2-1 is the most directly applicable standard for medical device cybersecurity testing. It builds on the general UL 2900-1 framework with healthcare-specific criteria, including structured penetration testing and SBOM analysis, and aligns with the FDA’s Medical CAP program. The FDA formally recognized it in 2018 to streamline premarket reviews for network-connectable healthcare products.

ISO 14971 governs how pen test findings must be integrated into the overall risk management file. Findings aren’t standalone observations. They become inputs to the risk analysis. Supporting frameworks include NIST SP 800-115 for test methodology documentation, IEC 62304 for software lifecycle context, and PTES as an execution standard. Your provider must know which of these apply to your specific submission type and reference them explicitly in the report. For guidance on interpreting and applying FDA cybersecurity guidance in practice, see an industry analysis on navigating FDA’s cybersecurity guidance.

Firmware and hardware pen testing: IVDs and other device categories

The same principles apply across device categories, including in vitro diagnostic (IVD) devices. IVD penetration testing follows the same FDA premarket cybersecurity guidance and must address all relevant attack surfaces, hardware interfaces, firmware, network connectivity, and companion software. The complexity of the scope scales with the device, but the evidentiary requirements are consistent across device pen test services regardless of classification or intended use.

What qualifications to require from a testing provider

Credentials matter, but they’re only part of the picture. The more important question is whether a provider has produced FDA-accepted pen test reports for medical devices in actual premarket submissions.

Certifications that signal genuine expertise

See also: CAN Bus and CANopen Vulnerabilities in Medical Devices, Fuzz Harness Generation for Medical Devices: HL7, DICOM, BLE GATT, MQTT, CoAP, and Proprietary Binary Protocols, and Robustness & Fuzz Testing for Medical Device Cybersecurity.

Require certifications like OSCP, GPEN, or CPENT for hands-on exploitation capability. These validate practical skills, not just theoretical knowledge. When combined with medical device-specific credentials tied to UL 2900, IEC 60601, or ISO 14971, they signal a tester who understands both the technical execution and the regulatory context.

ISO-accredited lab experience for FDA or CE mark processes adds meaningful credibility for submission-bound testing. Certifications alone, however, aren’t enough. Ask for documented case examples of actual medical device engagements, not healthcare IT work. Testing a hospital’s network is categorically different from testing a Class II connected monitor or a Class III implantable device.

Medical device-specific experience and FDA report track record

The provider must have hands-on experience testing hardware, firmware, radio protocols, and companion apps under real device conditions without degrading essential performance. They should know how to conduct passive scanning for devices in clinical use and active testing in controlled lab environments. They should also understand embedded systems, device communication protocols, and the specific vulnerabilities that appear in medical device architectures.

Most critically, they should have produced pen test reports included in successful premarket submissions across 510(k), De Novo, or PMA pathways. Blue Goat Cyber builds its pen test deliverables to FDA submission documentation standards from the outset, not retrofitted from a general IT template after the fact. The goal is a report structured to the evidentiary requirements FDA reviewers apply during premarket review, which means fewer deficiencies and a cleaner path to clearance.

What a good FDA-aligned pen test report actually looks like

A submission-ready report connects every element: scope, testing boundaries, methodology, findings, and risk conclusions. An FDA reviewer should be able to follow the logic from scope definition through risk conclusion without needing a clarification call.

• Scope and testing boundaries defined and tied to the threat model
• Methodology referenced by standard (PTES, NIST SP 800-115), and supported by a clear penetration testing checklist for execution and evidence collection
• All findings mapped to patient safety impact using an ISO 14971-aligned harm matrix
• Unaddressed findings documented with mitigation rationale, not silently omitted
• Report structured for eSTAR submission requirements

What pen testing costs and how long it takes

Budget and timeline vary significantly based on device complexity, regulatory scope, and provider type. Here’s what the market looks like in 2026.

Cost ranges by device complexity

Simple Class II devices, such as wireless sensors or basic patient monitors, typically run between $10,000 and $30,000 with timelines of two to six weeks. Complex Class II and Class III devices, including imaging systems, networked implantables, and surgical platforms, range from $30,000 to $100,000 or more, with timelines extending four to twelve weeks or longer, depending on scope depth.

Boutique specialized firms tend to be more cost-efficient than large consultancies for medical device work, provided they have the right expertise. The concern with lower-cost general IT security firms isn’t the upfront price, it’s the expensive rework that follows an FDA deficiency letter citing an inadequate pen test report.

What drives price and timeline differences

Device complexity is the largest cost driver. Multi-component, networked, or implantable systems require significantly more testing depth across firmware, hardware teardown, radio protocols, and cloud infrastructure. A device with a single Bluetooth interface costs far less to test thoroughly than a surgical platform with multiple wireless protocols, a cloud backend, and a companion mobile app.

Regulatory scope adds cost as well. FDA submission requirements, ISO 14971 integration, and HIPAA alignment all extend the engagement beyond a standard test-and-report cycle. Provider type also matters: the cheapest option is rarely the least expensive when you account for the full submission lifecycle.

Questions to ask before you sign a contract

Use these questions during vendor evaluation. The answers will tell you quickly whether a firm understands the medical device context or is applying general IT methodology to a regulated hardware problem.

Questions about scope and methodology

Ask how the provider determines what’s in scope for firmware, hardware, and wireless testing. The answer should reference your threat model and SBOM, not a generic checklist. Ask which standards (specifically PTES, NIST SP 800-115, or UL 2900-2-1) will be explicitly referenced in the methodology section of their report. Ask whether they’ve tested devices of similar architecture and connectivity to yours, and ask for specifics.

Questions about deliverables and FDA readiness

Request a sample report that has been included in a premarket submission. If they can’t provide one, that’s your answer. Ask how they map findings to patient harm potential under ISO 14971, and ask what format the final report will take. Confirm it’s structured for eSTAR submission requirements, not a corporate compliance format that would need translation before it can be submitted.

Red flags that signal the wrong firm

Walk away from firms that can’t name a single medical device-specific standard when you ask about their methodology. Watch for sample reports that use CVSS severity scores alone without safety impact framing. Be cautious of providers who propose repurposing an existing enterprise pen test template rather than building scope from your threat model. And if they have no experience with FDA deficiency responses when a submission is questioned on cybersecurity grounds, you’re taking on risk they aren’t equipped to help you manage.

Choosing right the first time

Medical device pen testing is a distinct discipline. The firm you choose directly affects your submission outcome and your device’s real-world security posture for every patient who uses it. Technical testing skill is necessary but not sufficient. Your provider must also understand how to produce evidence that satisfies FDA reviewers, integrates with your risk management file, and holds up under scrutiny across the full premarket review process.

Report quality matters as much as testing quality. A technically excellent test that produces an FDA-incompatible report is a costly mistake, one that delays clearance and forces rework at the worst possible time in your development cycle. The right provider brings both together from day one.

Blue Goat Cyber supports medical device manufacturers through the full penetration testing and submission documentation process, from scope definition through FDA-ready deliverables. If you’re preparing a premarket submission and need a pen test built for FDA review, contact Blue Goat Cyber to discuss your device and submission timeline.

How Blue Goat approaches this

Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result.

Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our medical device cybersecurity services for the full scope. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.

FAQ

What is medical device penetration testing?

Medical device penetration testing systematically identifies cybersecurity vulnerabilities in medical devices across hardware, firmware, software, and cloud components. It evaluates potential exploits and their impact on device safety and effectiveness, distinct from general IT security assessments.

How does FDA premarket guidance impact pen testing?

The FDA's February 3, 2026 final guidance specifically recommends penetration testing for cybersecurity verification. It mandates that reports detail methodology, tester independence, exploited vulnerabilities, and a patient harm impact assessment, ensuring regulatory alignment for premarket submissions.

Why is patient safety critical in medical device pen testing?

Patient safety matters. Testers must evaluate findings based on their potential to harm patients, not solely on technical severity scores. This aligns with ISO 14971 risk management principles required by the FDA.

What qualifications should a pen testing provider have?

A qualified provider should possess certifications like OSCP and have hands-on experience with medical device hardware, firmware, and wireless protocols. Crucially, they must have a proven track record of generating FDA-accepted penetration test reports for medical device premarket submissions.

Does UL 2900 apply to medical device pen testing?

Yes, UL 2900-2-1 is a key standard, providing healthcare-specific criteria for medical device cybersecurity, including penetration testing and SBOM analysis. The FDA formally recognized it to streamline premarket reviews for network-connectable devices.

What should an FDA-aligned pen test report include?

An FDA-aligned report must include a detailed device description, testing timeframe and methodology, tester credentials and independence, a full account of vulnerabilities (even unexploited ones), technical effects on safety and effectiveness, and a patient harm matrix. CVSS scores alone are insufficient.

Related: Medical Device Cybersecurity: A Complete Lifecycle Guide

About the author

Christian Espinosa, CISSP, Founder, Blue Goat Cyber. Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. Read more about Christian.